The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.
Grayscale Investments introduces the Dogecoin Trust with a 2.5% fee, fueling institutional interest. DOGE rebounds from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback